Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 123
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
5/8/2007
 
First Published:
11/1/2000
1.
Phase II/III Randomized Study of Transplantation With Unmodified Versus T-Cell-Depleted, Unrelated Allogeneic Bone Marrow in Patients With Leukemia (Summary Last Modified 12/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
Under 46
Other
UMN-MT-1995-06
UMN-9224, UMN-MT-9506, NCI-V00-1605, NCT00006451
Last Modified:
7/11/2007
 
First Published:
4/1/1998
2.
Phase II/III Randomized Study of Conventional vs T cell Depleted Unrelated Donor Bone Marrow Transplantation for Leukemia, Myelodysplasia, and Lymphoblastic Lymphoma (Summary Last Modified 02/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
55 and under
NCI
MCV-CCHR-9504-2X
DUMC-75951, NCI-G98-1388, NCT00003187
Last Modified:
7/11/2007
 
First Published:
2/1/2000
3.
Phase II/III Randomized Study of Processed Versus Unprocessed Unrelated Bone Marrow Transplantation in Patients With Acute or Chronic Leukemia or Myelodysplastic Syndromes
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Supportive care, Treatment
Completed
12 to 50
Other
CHIMERIC-HM01
WSU-10-02-99-M01-FB, NCT00004255
4.
Phase I/III Induction with ADR/ARA-C/VCR/PRDL and Consolidation and Maintenance with ADR/ARA-C, ADR/AZC, MePRDL/VCR/6-MP/MTX, or ARA-C for ANLL
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase I
Treatment
Closed
under 50
DFCI-76006
DFCI-VAPA-10
Last Modified:
5/4/2007
5.
Phase III Randomized Study of Sequential Treatment with 3 Noncross-Resistant Chemotherapy Combinations or Standard Chemotherapy for Poor-Prognosis Intermediate Grade and Immunoblastic non-Hodgkin's Lymphoma: IDA/CDDP/ARA-C/MePRDL, IDA/VCR/BLEO/CTX/MePRDL, and IFF/DHAD/VP-16 vs Standard CHOP (Summary Last Modified 09/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
over 15
NCI
MDA-DM-94017
NCI-T94-0040D, NCT00002565, T94-0040
Last Modified:
5/8/2007
 
First Published:
11/1/1994
6.
Phase III Randomized Study of Standard Therapy with ABCM (DOX/BCNU/CTX/L-PAM) vs Intensive Therapy with C-VAMP (CTX/VCR/DOX/MePRDL) Followed by High-Dose L-PAM (with or without TBI) with Hematopoietic Rescue, Both with IFN-A Maintenance, for Previously Untreated Myeloma (Summary Last Modified 03/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
under 65
MRC-LEUK-MYEL-VII
EU-94030, NCT00002599
Last Modified:
6/6/2005
7.
Phase III Study of Adjuvant Low-Dose Involved-Field Radiotherapy vs No Adjuvant Therapy in Children with Hodgkin's Disease in CR Following Chemotherapy Assigned by Clinical Stage (Summary Last Modified 02/1999)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
under 21 at diagnosis
NCI
CCG-5942
CCG-5942
Last Modified:
3/10/2004
8.
Phase III Randomized Study of High-Dose Sequential Chemotherapy Followed by Peripheral Blood Stem Cell Transplantation vs Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) for Poor-Risk, Intermediate- and High-Grade Non-Hodgkin's Lymphoma (Summary Last Modified 02/1999)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 to 65
NCI
E-2493
E2493
Last Modified:
12/5/2002
9.
Phase III Randomized Study of Early Intensification Versus Alternating Triple Chemotherapy in Patients With Intermediate-Grade or Immunoblastic Lymphoma With Poor Prognosis
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
15 to 59
NCI
MDA-DM-95121
NCI-V96-1010, NCT00002835
Last Modified:
11/28/2006
 
First Published:
4/1/1998
10.
Phase III Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Sequential High-Dose Chemotherapy With Autologous Peripheral Blood Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 to 60
Other
SWS-SAKK-38/97
EU-97037, NCT00003215
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute